Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental
| Autor: | Nikolaos Ziras, C. Kalofonos, Christos N. Papandreou, Pavlos Papakotoulas, Ioannis Boukovinas, Georgios Koumakis, Georgios Samelis, Helen Stergiou, Eleni Timotheadou, Evangelos Bournakis, Athina Christopoulou, Georgios Papatsimpas, Athanasios Athanasiadis, Gerasimos Aravantinos, Alexandros Bokas, Alexandros Ardavanis, Paris Makrantonakis, Ioannis Varthalitis, Maria Souggleri, Pavlos Papakostas, Epameinondas Samantas, Charalambos Andreadis, Nikolaos Tsoukalas, Anastasios Grivas, Sofia Tripodaki, Georgios Pentheroudakis |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Bevacizumab medicine.drug_class Low molecular weight heparin Hemorrhage 03 medical and health sciences 0302 clinical medicine Risk Factors Neoplasms Internal medicine medicine Humans Cancer associated thrombosis Cause of death business.industry Cancer Thrombosis General Medicine Tinzaparin Middle Aged medicine.disease Oncology 030220 oncology & carcinogenesis Female Observational study Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Anticancer Research. 40:305-313 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.13954 |
| Popis: | Background Cancer-associated thrombosis (CAT), the second leading cause of death in patients with cancer can be treated with low molecular weight heparin (LMWH) according to guidelines. Patients and methods A multicenter prospective observational study was carried out to record anti-thrombotic treatment practice, assess thrombosis recurrence and bleeding, and identify potential risk factors. Adult patients from 18 Oncology Departments throughout Greece were followed-up for 12 months. Results A total of 120 patients with CAT receiving anticoagulant treatment were enrolled (35% incidental); 85% were treated for more than 6 months, 95.8% were treated with tinzaparin and smaller percentages with other agents. Thrombosis recurred in three patients and there was minor bleeding in four patients. Bleeding was associated with high body mass index (>35 kg/m2), trauma history, renal insufficiency and bevacizumab use. Conclusion Incidental thrombosis contributes significantly to CAT burden. Long-term use of LMWH seems to be effective and safe. Several risk factors associated with bleeding should be considered during anti-coagulation therapy planning. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|